Skip to main content
. Author manuscript; available in PMC: 2016 Jan 6.
Published in final edited form as: Autoimmunity. 2010 Sep 9;43(8):682–689. doi: 10.3109/08916934.2010.506207

Figure 1.

Figure 1

dsDNA inhibits IgG purified from three SLE-ITP patients binding to GPIIIa49-66.(A) Binding activity of serum IgG from nine SLE-ITP patients and six healthy subjects to dsDNA and platelet GPIIIa49-66. IR refers to irrelevant peptide. SEM is given. (B) Presence of anti-GPIIIa antibodies in SLE-ITP patients. Twenty-five micrograms of platelet lysis were separated by 12% SDS-PAGE gels; transferred to a PVDF membrane; and immunoblotted with patient sera(lane P4-P7), normal sera(lane N1-N4), and mouse monoclonal Ab against platelet integrin GPIIIa (lane 1), respectively. (C) Blocking of IgG purified from SLE-ITP patients binding to GPIIIa49-66 peptide by dsDNA. Affinity-purified patient anti-dsDNA antibodies incubated with varying concentrations of dsDNA as indicated before ELISA.